^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Brain Cancer

    Related cancers:
    1d
    Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Alabama at Birmingham | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    temozolomide
    1d
    EMBRAIN: Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue (clinicaltrials.gov)
    P3, N=50, Recruiting, Odense University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    GDW: Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Region Stockholm | Enrolling by invitation --> Recruiting
    Enrollment status
    1d
    Study of GC101 TIL in Brain Glioma (Soochow2) (clinicaltrials.gov)
    P1, N=50, Recruiting, Shanghai Juncell Therapeutics | Trial completion date: May 2025 --> May 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • GC101 TIL
    1d
    Intravital Microscopy in Human Solid Tumors (clinicaltrials.gov)
    P=N/A, N=85, Recruiting, Mayo Clinic | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    1d
    Treatment strategies and innovation for recurrent high-grade glioma. (PubMed, J Neurooncol)
    Despite poor overall outcomes, incremental progress across targeted, immune, and delivery-based approaches supports a patient centered strategy emphasizing clinical-trial enrollment, molecular profiling and symptom focused care.
    Review • Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • IDH mutation + BRAF V600E
    |
    Avastin (bevacizumab) • temozolomide • lomustine
    1d
    Skull base foramina provide a route for the exit of brain lymphatic vessels from the human skull. (PubMed, Surg Radiol Anat)
    Our findings can increase the understanding of how LVs exit the skull and contribute to the neuropathophysiological processes. Knowledge of the lymphatic network is important for identifying metastatic sites of various cancers. Furthermore, special attention should be given during regional surgery to preserve lymphatic drainage.
    Journal
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • LYVE1 (Lymphatic vessel endothelial hyaluronan receptor 1)
    1d
    RBM7 suppresses mitochondrial dysfunction and ferroptosis by destabilizing FBXL16 mRNA to enhance Temozolomide resistance in glioblastoma. (PubMed, Mol Genet Genomics)
    An actinomycin D assay analyzed FBXL16 mRNA stability. RBM7 promotes TMZ resistance by suppressing mitochondrial dysfunction and ferroptosis through destabilization of FBXL16. Targeting the RBM7-FBXL16 axis may represent a novel strategy to overcome GBM chemoresistance.
    Journal
    |
    ATF4 (Activating Transcription Factor 4) • TCF4 (Transcription Factor 4)
    |
    temozolomide • dactinomycin
    1d
    Fgl2-knockout tumor cells serve as a vaccine inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges. (PubMed, Cancer Lett)
    Proteomic analysis found that Fgl2-KO-mediated suppression of CD47 occurred through the Src and PKCα pathways; inhibition of either pathway reduced CD47 expression. This study is the first to show that disrupting the Fgl2-CD47 circuit in tumor cells impairs their tumorigenic properties and induces long-term brain TRM cells, thereby providing new strategies for improving the efficacy of currently used whole tumor-cell vaccines.
    Journal
    |
    CD47 (CD47 Molecule)
    1d
    BTSCs exosomes derived NamiRNA-enhancer network of miR-151a-3p mediates a positive feedback loop and promotes the progression of glioma via FAK phosphorylation. (PubMed, Cancer Lett)
    Both in vitro and in vivo experiments demonstrated that exosomal miR-151a-3p promotes glioma cell migration, invasion, proliferation, and epithelial‒mesenchymal transition, thereby increasing tumour aggressiveness. These findings highlight the NamiR-151a-3p/PDE4D/FAK/YAP axis as a promising therapeutic target for GBM.
    Review • Journal
    |
    PDE4D (Phosphodiesterase 4D)
    1d
    Deciphering the role of angiogenesis in glioblastoma: Integrative insights from transcriptomic profiling, single-cell sequencing and interpretable machine learning approaches. (PubMed, Pathol Res Pract)
    In summary, our research established the ARG-derived prognostic signature validated across independent GBM cohorts and revealed concomitant immune and mechanical niche dysregulation in high-risk patients. The rationale for combined angiogenesis/stroma/immune modulation strategies was provided, with FSCN1 proposed as the potential therapeutic target.
    Journal
    |
    AEBP1 (AE Binding Protein 1) • VIM (Vimentin) • CD31 (Platelet and endothelial cell adhesion molecule 1) • FSCN1 (Fascin Actin-Bundling Protein 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • BMP2 (Bone Morphogenetic Protein 2) • SEMA3G (Semaphorin 3G)